Our team of savvy editors independently handpicks all recommendations. If you make a purchase through our links, we may earn a commission. Deals and coupons were accurate at the time of publication ...

Moderna Inc.’s chief executive officer said the company doesn’t plan to invest in new late-stage vaccine trials because of growing opposition to immunizations from US officials. “You cannot make a ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

CHONGQING, CHINA - JULY 29: In this photo illustration, a smartphone displays the logo of Moderna Inc. (NASDAQ: MRNA), a biotechnology company known for its mRNA-based vaccines and therapeutics, in ...

Moderna's and Merck's partnership could help to advance cancer care. A promising skin cancer trial might have broader implications for other types of tumor treatments. Five-year follow-up data from a ...

Moderna (MRNA) CEO Stéphane Bancel said on Thursday that his company will not fund further late-stage development of vaccines as the U.S. government pushes back against immunizations. “We have said ...

In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

Jan 22 (Reuters) - Moderna does ‌not plan to ‌invest in new late-stage vaccine trials because of growing opposition to ‍immunizations from U.S. officials, CEO Stephane Bancel said ⁠in an interview ...

The current COVID-19 pandemic has claimed an estimated 18.2 million lives globally 1, but it could have been worse. Without vaccines, the death toll could have been closer to 40 million 2. A future ...

Moderna is on a roll, with investors hopeful that positive results from a cancer vaccine trial can revive the pharma stock after a stagnant run.